Cargando…

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar

This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease activator receptor-1, which prevents thrombin from activating platelets. Two Phase III clini...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cheng, Judy WM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913541/ https://www.ncbi.nlm.nih.gov/pubmed/27366081 http://dx.doi.org/10.2147/VHRM.S81342

Ejemplares similares

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Management of atrial fibrillation: focus on the role of dronedarone
por: Cheng, Judy WM
Publicado: (2011)

Current perspectives on the role of the pharmacist in heart failure management
por: Cheng, Judy WM
Publicado: (2018)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

The Dual Role of Platelets in the Cardiovascular Risk of Chronic Inflammation
por: Zamora, Carlos, et al.
Publicado: (2021)

Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases
por: Irfan, Muhammad, et al.
Publicado: (2020)

The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
por: Ali, Ahmed Ali Gebril, et al.
Publicado: (2023)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

The Role of Vitamin D in Reducing the Risk of Metabolic Disturbances That Cause Cardiovascular Diseases
por: Al-Oanzi, Ziad H., et al.
Publicado: (2023)

Depression and Cardiovascular Disease: The Viewpoint of Platelets
por: Amadio, Patrizia, et al.
Publicado: (2020)

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring
por: Procyk, Grzegorz, et al.
Publicado: (2022)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Azilsartan/chlorthalidone combination therapy for blood pressure control
por: Cheng, Judy WM
Publicado: (2013)

CKD Effects on Platelets: Implications for Cardiovascular Risk
por: Baaten, Constance C.F.M.J., et al.
Publicado: (2022)

Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
por: Terui, Hitoshi, et al.
Publicado: (2023)

Mean Platelet Volume as a Marker of Vasculogenic Erectile Dysfunction and Future Cardiovascular Risk
por: Crafa, Andrea, et al.
Publicado: (2020)

The Impact of Flavonols on Cardiovascular Risk
por: Popiolek-Kalisz, Joanna, et al.
Publicado: (2022)

Role of platelets and platelet receptors in cancer metastasis
por: Schlesinger, Martin
Publicado: (2018)

Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding
por: Veninga, Alicia, et al.
Publicado: (2020)

Editorial: Role of the Platelet Phenomenon in Cardiovascular Diseases and Cancer
por: Panova-Noeva, Marina, et al.
Publicado: (2022)

Platelet–Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases
por: Pluta, Kinga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v5k34985kchr2jtai3dm19q5sp